2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W012267
    2-Bromo-2'-methoxyacetophenone 31949-21-0 ≥98.0%
    2-Bromo-2'-methoxyacetophenone is an irreversible inhibitor for MurA, that inhibits MurA in E. coli with an IC50 of 0.38 μM. 2-Bromo-2'-methoxyacetophenone can be used in antibacterial research for blocking bacterial cell wall synthesis.
    2-Bromo-2'-methoxyacetophenone
  • HY-W015399
    4-Methylcinnamic acid 1866-39-3 99.63%
    4-Methylcinnamic acid, a Cinnamic acid analog, can be used as a intervention catalyst for overcoming antifungal tolerance. 4-Methylcinnamic acid can improve the potency of cell wall-disrupting agents.
    4-Methylcinnamic acid
  • HY-W150677
    BioA-IN-1 77820-11-2 99.24%
    BioA-IN-1 (Compound 15) is an inhibitor of BioA, a key enzyme in the biotin synthesis pathway of Mycobacterium tuberculosis, with an IC50 value of 0.195 μM. BioA-IN-1 exhibits antibacterial activity but has no cytotoxicity.
    BioA-IN-1
  • HY-W017162R
    DL-3-Phenyllactic acid (Standard) 828-01-3
    DL-3-Phenyllactic acid (Standard) is the analytical standard of DL-3-Phenyllactic acid. This product is intended for research and analytical applications. DL-3-Phenyllactic acid is a broad-spectrum antimicrobial compound.
    DL-3-Phenyllactic acid (Standard)
  • HY-W250308A
    ε-Poly-L-lysine (hydrochloride) (MV 2000-5000)
    ε-Poly-L-lysine hydrochloride (MV 2000-5000) is an antimicrobial peptide that can be produced by bacteria such as Streptomyces. Epsilon-polylysine hydrochloride inhibits the growth of microorganisms such as bacteria, yeasts and molds and is therefore often used as a green food additive and preservative in various food and beverage products. Epsilon-polylysine hydrochloride has a variety of properties, including thermal stability, resistance to acidic conditions, and broad-spectrum antimicrobial activity. Epsilon-polylysine hydrochloride can be loaded on other materials to form nanoparticles or form nanofiber membranes for targeted delivery to exert sustained antibacterial efficacy. Epsilon-polylysine hydrochloride is also used as a liposome stabilizer.
    ε-Poly-L-lysine (hydrochloride) (MV 2000-5000)
  • HY-13321
    Anguizole 442666-98-0 99.53%
    Anguizole is a small molecule inhibitor of HCV replication and alters NS4B's subcellular distribution.
    Anguizole
  • HY-13740S
    Resiquimod-d5 2252319-44-9 99.84%
    Resiquimod-d5 is deuterium labeled Resiquimod. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.
    Resiquimod-d5
  • HY-17412A
    Minocycline 10118-90-8 98.59%
    Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect.
    Minocycline
  • HY-Y0248AS
    (E,​E)​-​Farnesol-d6 166447-71-8 98.56%
    (E,​E)​-​Farnesol-d6 is deuterium labeled Farnesol. Farnesol is a sesquiterpene alcohol that modulates cell-to-cell communication in Candida albicans, and has the activity in inhibiting bacteria.
    (E,​E)​-​Farnesol-d6
  • HY-19447
    Besifovir 441785-25-7 ≥98.0%
    Besifovir (LB80331), a parent agent converted by LB80380 (HY-19447A), further metabolizes to its active form, LB80317 (HY-106235). Besifovir is an orally active, novel antiviral agent against hepatitis B virus (HBV).
    Besifovir
  • HY-19558
    IDX184 1036915-08-8 99.80%
    IDX184 is a potent and orally bioavailable inhibitor of HCV replication. IDX184 potently inhibits HCV polymerase (IC50=0.31 μM, Ki=52.3 nM).
    IDX184
  • HY-P2292
    Omiganan, FITC labeled 98.29%
    Omiganan, FITC labeled is a peptide-FITC complex composed of Omiganan and a FITC. Omiganan is a bactericidal and fungicidal cationic peptide being developed as a topical gel for prevention of catheter-associated infections. FITC is a derivative of fluorescein for the labeling of amines.
    Omiganan, FITC labeled
  • HY-100531
    DprE1-IN-2 1615713-87-5 98.94%
    DprE1-IN-2 (compound 18) is a potent DprE1 inhibitor with an IC50 of 28 nM. DprE1-IN-2 has antituberculosis effect.
    DprE1-IN-2
  • HY-101866
    KKL-35 865285-29-6 99.47%
    KKL-35 is a trans-translation tagging reaction inhibitor with an IC50 of 0.9 μM.
    KKL-35
  • HY-111759
    Jaspamycin 22242-96-2 98.60%
    Jaspamycin (7-CN-7-C-Ino) is a potent activator of PKA, binding to the R site (PKAR), with an EC50 of 6.5 nM and Kd of 8 nM in Trypanosoma brucei. Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα. Anti-parasite activity.
    Jaspamycin
  • HY-112564
    JNJ-632 1572510-42-9 99.94%
    JNJ-632 is a hepatitis B virus (HBV) capsid assembly modulator (CAM).
    JNJ-632
  • HY-123561
    MMV008138 1679333-73-3 98.49%
    MMV008138 is a species-selective IspD (enzyme 2-C-methyl-d-erythritol 4-phosphate cytidylyltransferase)-targeting antimalarial agent, with an IC50 of 44 nM for PfIspD (P. falciparum IspD). MMV008138 inhibits the growth of P. falciparum Dd2 strain with an IC50 of 250 nM.
    MMV008138
  • HY-124662
    IHVR-19029 1447464-73-4 ≥98.0%
    IHVR-19029 is a potent endoplasmic reticulum (ER) α-glucosidases I and II inhibitor, with an IC50 of 0.48 μM for ER a-glucosidase I. IHVR-19029 efficiently blocks the replication of several hemorrhagic fever viruses, such as Dengue virus (DENV), Ebola virus (EBOV) and Rift Valley fever virus. The combination of IHVR-19029 with Favipiravir (HY-14768) improves the antiviral efficacy.
    IHVR-19029
  • HY-128866
    TBAJ-876 2332841-25-3 98%
    TBAJ-876 is the inhibitor of mycobacterium tuberculosis. TBAJ-876 is the analogue of the anti-tuberculosis agent Bedaquiline. TBAJ-876 has the potential for the research of tuberculosis.
    TBAJ-876
  • HY-137453
    Tenofovir amibufenamide 1571076-26-0 99.67%
    Tenofovir amibufenamide (HS-10234), a Tenofovir prodrug, is an orally active antiviral agent. Tenofovir amibufenamide inhibits HBV, and can be used for chronic hepatitis B (CHB) study.
    Tenofovir amibufenamide
Cat. No. Product Name / Synonyms Application Reactivity